Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: A 6-month prospective study

Vaccine

Volumn 30, Issue 12, 2012, Pages 2047-2050

  Drolet, Mélanie ^a,b   Levin, Myron J ^c   Schmader, Kenneth E ^d,e   Johnson, Robert ^f   Oxman, Michael N ^g   Patrick, David ^h   Fournier, Simon Olivier ^a   Mansi, James A ⁱ   Brisson, Marc ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DURHAM VA MEDICAL CENTER   (United States)

^f BRISTOL ROYAL INFIRMARY   (United Kingdom)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Absenteeism; Herpes zoster; Postherpetic neuralgia; Presenteeism; Work productivity

Indexed keywords

ABSENTEEISM; ADULT; ARTICLE; CANADA; DISEASE DURATION; DISEASE SEVERITY; EMPLOYMENT STATUS; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; IMMUNOCOMPETENCE; MAJOR CLINICAL STUDY; MALE; PAIN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PRODUCTIVITY; PROSPECTIVE STUDY; RASH; WORK CAPACITY;

ABSENTEEISM; AGED; AGED, 80 AND OVER; CANADA; EFFICIENCY; FEMALE; HERPES ZOSTER; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PROSPECTIVE STUDIES;

EID: 84862803493     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.045     Document Type: Article

References (19)

1. Brisson M., Edmunds W.J., Law B., Gay N.J., Walld R., Brownell M., et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001, 127(October (2)):305-314.
2. Insinga R.P., Itzler R.F., Pellissier J.M., Saddier P., Nikas A.A. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005, 20(August (8)):748-753.
3. Drolet M., Brisson M., Schmader K., Levin M., Johnson R., Oxman M., et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain 2010, 11(November (11)):1211-1221.
4. Opstelten W., Zuithoff N.P., van Essen G.A., van Loon A.M., van Wijck A.J., Kalkman C.J., et al. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain 2007, 132(November (Suppl. 1)):S52-S59.
5. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002, 18(November-December (6)):350-354.
6. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352(June (22)):2271-2284.
7. Coplan P.M., Schmader K., Nikas A., Chan I.S., Choo P., Levin M.J., et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004, 5(August (6)):344-356.
8. Yawn B.P., Saddier P., Wollan P.C., St Sauver J.L., Kurland M.J., Sy L.S. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007, 82(November (11)):1341-1349.
9. Merck Canada Inc. Monographie de produit: Zostavax; 2011.
10. Brisson M., Pellissier JM, Camden S, Quach C, De Wals P The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin 2008, 4(May-June (3)):238-245.
11. Pellissier J.M., Brisson M., Levin M.J. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007, 25(November (49)):8326-8337.
12. Drolet M., Brisson M., Levin M.J., Schmader K.E., Oxman M.N., Johnson R.W., et al. A prospective study of the herpes zoster severity of illness. Clin J Pain 2010, 26(October (8)):656-666.
13. Aronsson G., Gustafsson K., Dallner M. Sick but yet at work. An empirical study of sickness presenteeism. J Epidemiol Community Health 2000, 54(July (7)):502-509.
14. Prochaska J.O., Evers K.E., Johnson J.L., Castle P.H., Prochaska J.M., Sears L.E., et al. The well-being assessment for productivity: a well-being approach to presenteeism. J Occup Environ Med 2011, 53(July (7)):735-742.
15. Scott F.T., Johnson R.W., Leedham-Green M., Davies E., Edmunds W.J., Breuer J. The burden of herpes zoster: a prospective population based study. Vaccine 2006, 24(February (9)):1308-1314.
16. Singhal P.K., Makin C., Pellissier J., Sy L., White R., Saddier P. Work and productivity loss related to herpes zoster. J Med Econ 2011, 14(5):639-645.
17. White R.R., Lenhart G., Singhal P.K., Insinga R.P., Itzler R.F., Pellissier J.M., et al. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics 2009, 27(9):781-792.
18. Stewart W.F., Ricci J.A., Chee E., Morganstein D. Lost productive work time costs from health conditions in the United States: results from the American productivity audit. J Occup Environ Med 2003, 45(December (12)):1234-1246.
19. Statistics Canada Information sur la population active; 2011.